Holen Sie sich die Stockscreener-App
1.26
1.17%
-0.02
Schlusskurs vom Vortag:
$1.28
Offen:
$1.26
24-Stunden-Volumen:
132.18K
Relative Volume:
0.04
Marktkapitalisierung:
$14.70M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-8.70M
KGV:
-0.8378
EPS:
-1.5039
Netto-Cashflow:
$-7.99M
1W Leistung:
+5.42%
1M Leistung:
+9.05%
6M Leistung:
-46.40%
1J Leistung:
+18.22%
1-Tages-Spanne:
$1.24
$1.29
1-Wochen-Bereich:
$1.21
$1.35
52-Wochen-Spanne:
$0.8127
$4.1899
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
Firmenname
Phio Pharmaceuticals Corp
Sektor
Branche
Telefon
(508) 767-3861
Adresse
411 SWEDELAND ROAD, KING OF PRUSSIA, MA
Compare PHIO vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PHIO
Phio Pharmaceuticals Corp
|
1.265 | 14.87M | 0 | -8.70M | -7.99M | -1.5039 |
VRTX
Vertex Pharmaceuticals Inc
|
433.58 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
762.40 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
747.05 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.89 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.74 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-05 | Fortgesetzt | H.C. Wainwright | Buy |
| 2020-08-05 | Eingeleitet | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp Aktie (PHIO) Neueste Nachrichten
Profit Review: Is Phio Pharmaceuticals Corp on track to beat earningsSwing Trade & Detailed Earnings Play Alerts - baoquankhu1.vn
VIX Spike: Is Phio Pharmaceuticals Corp being accumulated by smart moneyQuarterly Risk Review & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
PHIO Stock Price, Quote & Chart | PHIO PHARMACEUTICALS CORP (NASDAQ:PHIO) - ChartMill
Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762 - The National Law Review
Phio Pharmaceuticals Secures cGMP Manufacturing for Clinical Supply - The Globe and Mail
Phio Pharmaceuticals Signs U.S. cGMP Manufacturing Agreement for PH-762 Drug Product Clinical Supply - Minichart
Phio Pharmaceuticals secures U.S. cGMP manufacturer for PH-762 clinical and commercial supply - TradingView
Phio (NASDAQ: PHIO) inks PH-762 manufacturing deal after strong 65% response - Stock Titan
Phio lines up U.S. supply for skin cancer drug as PH-762 trials advance - Stock Titan
Dow Update: Can Phio Pharmaceuticals Corp lead its sector in growth - baoquankhu1.vn
Phio Pharmaceuticals Corp (44R1.MU) Stock Price, News, Quote & History - ca.finance.yahoo.com
Phio Pharmaceuticals Corp (44R1.MU) stock price, news, quote and history - Yahoo Finance UK
Financial Analysis: Galectin Therapeutics (NASDAQ:GALT) & Phio Pharmaceuticals (NASDAQ:PHIO) - Defense World
Phio Pharmaceuticals to present PH-762 cancer trial data Friday By Investing.com - Investing.com South Africa
Phio Pharmaceuticals to present PH-762 cancer trial data Friday - Investing.com
Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring Clinical Pipeline Advancement - marketscreener.com
A skin cancer study with 65% response sends Phio to a late-breaker stage - Stock Titan
Cancer biotech Phio Pharmaceuticals stock surges as trial shows tumor clearance at highest dose in skin cancer patients - MSN
Aug Macro: Is Phio Pharmaceuticals Corp a stock for growth or value investors2026 Historical Comparison & Step-by-Step Trade Execution Guides - baoquankhu1.vn
Retail Trends: Is Phio Pharmaceuticals Corp being accumulated by smart money2026 Performance Recap & Daily Entry Point Trade Alerts - baoquankhu1.vn
Phio Pharmaceuticals Announces "A Groundbreaking Approach to Treating Skin Cancer" in a Fireside Chat with Force Family Office - Bitget
Phio cancer study sees ~65% response; CEO in March 18 virtual chat - Stock Titan
Sidoti Boosts Earnings Estimates for Phio Pharmaceuticals - Defense World
PHIO: RNA therapy for skin cancer shows 85% response and no toxicities, advancing to pivotal trials - TradingView
Phio Pharmaceuticals Corp. Financial Disclosures & SEC Filings - TradingView
Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026 11 AM EDT - GlobeNewswire
Phio Pharmaceuticals to Present at the Life Sciences Investor Forum on March 12, 2026, 11 AM EDT - TMX Newsfile
Cancer gene-silencing trial shows 65% response in Phio study - Stock Titan
How Phio Pharmaceuticals Corp. stock compares to industry benchmarksBuy Signal & High Accuracy Trade Signal Alerts - Naître et grandir
EV Market: Is Phio Pharmaceuticals Corp being accumulated by smart moneyJuly 2025 Sector Moves & Free Accurate Trade Setup Notifications - baoquankhu1.vn
Phio Pharmaceuticals Reports 2025 Year-End Financial Results and Business Update - marketscreener.com
Cancer drug PH-762 completes safety phase as Phio raises $23.7M - Stock Titan
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series - marketscreener.com
Phio cancer drug PH-762 posts 65% response; CEO hosts live Q&A - Stock Titan
PHIO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Cancer Biotech Phio Pharmaceuticals Stock Surges As Trial Shows Tumor Clearance At Highest Dose In Skin Cancer Patients - Sahm
PHIO Should I Buy - Intellectia AI
PHIO Technical Analysis & Stock Price Forecast - Intellectia AI
Phio Pharmaceuticals Corp. Selected as B2i Digital Featured Company - Weekly Voice
Phio Pharmaceuticals Reports Promising Phase 1b Results for Skin Cancer Therapy, Plans FDA Submission for 2026 - citybuzz -
Phio Pharmaceuticals Aligns Leadership Team to Support Next Stage Development of PH-762 and Advancement of PH-894 - The Courier-Journal
Is Phio Pharmaceuticals Corp. stock trending bullish2025 Major Catalysts & Advanced Technical Analysis Signals - mfd.ru
Phio Pharmaceuticals Boosts CEO Severance and Incentive Compensation - TipRanks
Finanzdaten der Phio Pharmaceuticals Corp-Aktie (PHIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Phio Pharmaceuticals Corp-Aktie (PHIO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Bitterman Robert J | Chairman, Pres. & CEO |
Dec 23 '25 |
Buy |
1.02 |
5,000 |
5,100 |
286,421 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Nov 21 '25 |
Buy |
1.14 |
5,000 |
5,700 |
281,421 |
| Bitterman Robert J | Chairman, Pres. & CEO |
Nov 18 '25 |
Buy |
1.27 |
5,000 |
6,350 |
276,421 |
| Bitterman Robert J | Chairman, Pres & CEO |
Jun 10 '25 |
Buy |
2.42 |
2,000 |
4,840 |
27,149 |
| Ferrara Robert L | Director |
Jun 10 '25 |
Buy |
2.42 |
2,500 |
6,050 |
15,666 |
| Bitterman Robert J | Chairman, Pres & CEO |
Jun 09 '25 |
Buy |
2.75 |
1,500 |
4,125 |
25,149 |
| Bitterman Robert J | Chairman, Pres & CEO |
May 21 '25 |
Buy |
1.77 |
3,000 |
5,310 |
22,449 |
| Bitterman Robert J | Chairman, Pres & CEO |
May 22 '25 |
Buy |
1.78 |
1,200 |
2,136 |
23,649 |
| Ferrara Robert L | Director |
May 20 '25 |
Buy |
1.82 |
2,500 |
4,550 |
13,166 |
1.90%
1.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):